PFE - Pfizer Valneva complete recruitment for Phase 3 Lyme vaccine study
2023-12-04 17:49:57 ET
More on Pfizer, Valneva, etc.
- Pfizer: Slimming Down After COVID Franchise And Obesity Pipeline Setbacks
- Pfizer: Between Hope, Despair, And A 5.7% Yield
- Pfizer: Disastrous 2023 Hits New Low With Weight Loss Drug Failure
- Pfizer hits new 52-week low after weight loss setback
- Biggest stock movers today: Pfizer, Dell Technologies, Ulta Beauty, UiPath and more
For further details see:
Pfizer, Valneva complete recruitment for Phase 3 Lyme vaccine study